Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has received a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $35.70.

A number of brokerages recently issued reports on VRDN. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. BTIG Research raised their target price on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Royal Bank of Canada raised their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday.

Institutional Trading of Viridian Therapeutics

A number of institutional investors have recently bought and sold shares of VRDN. JPMorgan Chase & Co. raised its holdings in Viridian Therapeutics by 218.5% during the third quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after buying an additional 274,641 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Viridian Therapeutics by 1,603.4% during the third quarter. Principal Financial Group Inc. now owns 172,810 shares of the company’s stock valued at $3,931,000 after buying an additional 162,665 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in Viridian Therapeutics during the third quarter valued at about $8,917,000. Exome Asset Management LLC bought a new position in Viridian Therapeutics during the third quarter valued at about $3,968,000. Finally, Geode Capital Management LLC raised its holdings in Viridian Therapeutics by 5.8% during the third quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company’s stock valued at $33,979,000 after buying an additional 81,951 shares in the last quarter.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN opened at $18.20 on Friday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -4.22 and a beta of 1.13. The stock’s fifty day simple moving average is $20.54 and its 200 day simple moving average is $18.84. Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. As a group, sell-side analysts forecast that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.